Results 221 to 230 of about 393,600 (259)
Some of the next articles are maybe not open access.
Clinical Infectious Diseases, 2020
BACKGROUND Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, leads to significant morbidity and mortality worldwide. This review aimed to establish the effectiveness of meningococcal vaccines at preventing IMD and N.
M. McMillan +7 more
semanticscholar +1 more source
BACKGROUND Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, leads to significant morbidity and mortality worldwide. This review aimed to establish the effectiveness of meningococcal vaccines at preventing IMD and N.
M. McMillan +7 more
semanticscholar +1 more source
Invasive meningococcal disease: a disease of the endothelial cells
Trends in Molecular Medicine, 2014Neisseria meningitidis is an extracellular pathogen, which, once in the bloodstream, has the ability to form microcolonies on the apical surface of endothelia. Pathogen interaction with microvessels is mediated by bacterial type IV pili and two receptors on endothelial cells: CD147 and the β2-adrenoceptor.
Coureuil, Mathieu +3 more
openaire +3 more sources
Vaccine, 2020
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited.
W. D. Graaf, M. Knol, A. V. D. Ende
semanticscholar +1 more source
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited.
W. D. Graaf, M. Knol, A. V. D. Ende
semanticscholar +1 more source
Microbial Pathogenesis, 2019
Using the PRISMA guideline, 102 studies were included in this study. The highest and the lowest proportion of N. meningitidis serogroups in invasive meningococcal disease (IMD) was for NmB with 48.5% (95% CI: 45-52) and NmX with 0.7% (95% CI: 0.3-1.7 ...
Ali Purmohamad +6 more
semanticscholar +1 more source
Using the PRISMA guideline, 102 studies were included in this study. The highest and the lowest proportion of N. meningitidis serogroups in invasive meningococcal disease (IMD) was for NmB with 48.5% (95% CI: 45-52) and NmX with 0.7% (95% CI: 0.3-1.7 ...
Ali Purmohamad +6 more
semanticscholar +1 more source
Clinical progress note: Invasive meningococcal disease
Journal of Hospital MedicineAbstract Invasive meningococcal disease due to Neisseria meningitidis in the United States has decreased since the late 1990s, leading to fewer practicing clinicians with first‐hand experience in diagnosing and managing of the disease.
Alaina Shine, Erin Chung
openaire +1 more source
Invasive Meningococcal Disease in Childhood
Pediatrics In Review, 2011Anne F, Brayer, Sharon G, Humiston
openaire +2 more sources
Invasive meningococcal disease and HIV coinfection.
Communicable diseases intelligence quarterly report, 2002Three cases of meningococcal disease which occurred over a 3 year period in HIV-infected people living in the Wentworth Health Area of Sydney, Australia, are described. None of the 3 had ever received antiretroviral therapy which may, have contributed to development of invasive meningococcal disease.
openaire +1 more source
Invasive meningococcal disease in Spain 2023
Introduction: Description of the epidemiological analysis of invasive meningococcal disease (IMD) in Spain during 2023 and its comparison with previous years. Methods: Descriptive epidemiological analysis of cases of IMD reported to the National Epidemiological Surveillance Network (RENAVE) in 2023 was conducted.Soler Soneira, Marta +4 more
openaire
Invasive meningococcal disease prevention in Spain. Adult meningococcal vaccination
Vacunas (English Edition), 2019F.A. Moraga-Llop, M. Campins Martí
openaire +1 more source